The publication of full trial results from the MANDARA trial further underlines the potential of benralizumab (Fasenra) in the ability to help adult patients achieve remission of relapsing or refractory eosinophilic granulomatosis with polyangiitis.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045